Who are Qulipta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zavzpret, Ubrelvy, Nurtec Odt, Rimegepant 25 MG, Rimegepant for acute migraine treatment, Rimegepant 75mg Orally Disintegrating Tablets (ODT).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atogepant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Qulipta — Competitive Intelligence Brief

Qulipta (ATOGEPANT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcitonin Gene-related Peptide Receptor Antagonist [EPC]. Area: Neuroscience.

marketed Calcitonin Gene-related Peptide Receptor Antagonist [EPC] Calcitonin gene-related peptide type 1 receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Qulipta (ATOGEPANT) — AbbVie. Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Qulipta TARGET	ATOGEPANT	AbbVie	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	2021-01-01
Zavzpret	Zavegepant Hydrochloride	Pfizer	marketed	Calcitonin Gene-related Peptide Receptor Antagonist	Calcitonin gene-related peptide type 1 receptor	2023-01-01
Ubrelvy	UBROGEPANT	AbbVie	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	2019-01-01
Nurtec Odt	rimegepant	Pfizer	marketed	Calcitonin Gene-related Peptide Receptor Antagonist	calcitonin gene-related peptide receptor	2020-01-01
Rimegepant 25 MG	rimegepant-25-mg	Pfizer	marketed	calcitonin gene-related peptide receptor antagonist	calcitonin gene-related peptide receptor
Rimegepant for acute migraine treatment	rimegepant-for-acute-migraine-treatment	Pfizer	marketed	calcitonin gene-related peptide receptor antagonist	calcitonin gene-related peptide receptor
Rimegepant 75mg Orally Disintegrating Tablets (ODT)	rimegepant-75mg-orally-disintegrating-tablets-odt	Pfizer	marketed	calcitonin gene-related peptide receptor antagonist	calcitonin gene-related peptide receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcitonin Gene-related Peptide Receptor Antagonist [EPC] class)

AbbVie · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Qulipta — Competitive Intelligence Brief. https://druglandscape.com/ci/atogepant. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab